U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

Дата публикации: 13-07-2026 02:07:36

PRINCETON, N.J.--(BUSINESS WIRE) July 13, 2026-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for mezigdomide in combination with carfilzomib and...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	0	11.68	28-04-2026
2	Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors	0	13.2	08-07-2026
3	Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors	0	11.39	29-04-2026
4	Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer	0	15.81	02-07-2026
5	Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST	0	10.76	28-05-2026
6	Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma	0	16.87	26-06-2026
7	FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting	0	11.63	01-06-2026
8	Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA	0	8.85	28-04-2026
9	New Drug Application for Neladalkib in TKI Pre-Treated Advanced ALK-Positive NSCLC Accepted for Filing with Priority Review by the FDA	0	17.4	27-05-2026
10	Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)	0	12.6	30-06-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.44. Источник: www.drugs.com.